Holen Sie sich die Stockscreener-App
108.26
1.17%
1.25
Handel nachbörslich:
108.26
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Como - GuruFocus
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 - PR Newswire
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Deutsche Bank AG - Defense World
Cetera Investment Advisers Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Idiopathic Hypersomnia Treatment Market: Drug Pipeline, - openPR.com
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - Yahoo Finance
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences - Citizen Tribune
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Leadership to Present Strategic Updates at Two Major Healthcare Conferences in June - Stock Titan
Psychedelic Drugs Market Opportunities in the United States - openPR.com
Jazz Pharmaceuticals: One Step Forward, One Back (NASDAQ:JAZZ) - Seeking Alpha
Transcript : Jazz Pharmaceuticals plc Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Cut by Cubist Systematic Strategies LLC - Defense World
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook - Yahoo Finance
Mercer Global Advisors Inc. ADV Has $202,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
Jazz outlines $4.15B-$4.4B revenue target for 2025 amid growth in neuroscience portfolio and new oncology approvals - MSN
Weekly Investment Analysts’ Ratings Updates for Jazz Pharmaceuticals (JAZZ) - Defense World
July 18th Options Now Available For Jazz Pharmaceuticals - Nasdaq
Jazz Pharma stock falls after lowered full year guidance - MSN
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings May Just Be The Starting Point - Yahoo Finance
Jazz Pharmaceuticals (NASDAQ:JAZZ) Cut to “Hold” at StockNews.com - Defense World
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance - ADVFN
Jazz Pharmaceuticals at Bank of America 2025: Strategic Growth Amid Challenges - Investing.com Nigeria
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Avadel Pharma gains after appeals court ruling in Lumryz case with Jazz Pharma - MSN
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update - Yahoo Finance
Hikma $50M Deal to Settle Xyrem Antitrust Claims - USA Herald
Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st
Jazz Pharmaceuticals plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Royal Bank of Canada Has Lowered Expectations for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World
StockNews.com Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Buy - Defense World
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript - Insider Monkey
Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL - Law360
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case - Reuters
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - MSN
After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM) - The Globe and Mail
Jazz Earnings: Strong Demand for Epidiolex and Xywav Drive Growth; Shares Very Undervalued - Morningstar
Jazz Pharmaceuticals (NASDAQ:JAZZ) Shares Gap Down After Earnings Miss - Defense World
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Decoding Jazz Pharmaceuticals PLC (JAZZ): A Strategic SWOT Insig - GuruFocus
Jazz Pharmaceuticals (JAZZ) Rating Maintained Despite Price Target Cut | JAZZ Stock News - GuruFocus
RBC Capital Maintains Outperform Rating on Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ): Morgan Stanley Adjusts Price Target - GuruFocus
Jazz Pharmaceuticals (JAZZ) Target Price Lowered by Piper Sandler | JAZZ Stock News - GuruFocus
RBC Capital Adjusts Price Target for Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ) Price Target Reduced by Morgan Stanl - GuruFocus
Jazz Pharmaceuticals (JAZZ) Maintains Strong Momentum with 'Buy' Rating | JAZZ Stock News - GuruFocus
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):